MedElevator
Войти в исследования Endokrynologia Polska · 2026
Evaluation of incretin levels in patients with prolactinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Altunay Vurğun Gökçe, Yılmaz Nusret, Özdem Sebahat, Sarı Ramazan
Аннотация
INTRODUCTION: Prolactin has been shown to play an important role in the regulation of glucose metabolism. The present study aimed toevaluate incretin hormones in patients with prolactinoma.
MATERIAL AND METHODS: The study included 13 patients with prolactinoma without a history of diabetes and in 13 healthy volunteers.All participants underwent a 75-g oral glucose tolerance test (OGTT). Serum glucose, insulin, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were measured at 0, 30, 60, 90, and 120 minutes.
RESULTS: Serum glucose and insulin levels at baseline and during the OGTT were similar in both groups (p > 0.05). GLP-1 levels, including baseline values, area under the curve (AUC), and all time points during OGTT, were also comparable between the groups (p > 0.05).In contrast, baseline GIP (p = 0.024), AUC (p = 0.011), and GIP levels at 30, 90, and 120 minutes were significantly lower in patients withprolactinoma (p = 0.006, p = 0.015, and p = 0.035, respectively).
CONCLUSIONS: These findings suggest that incretins may play a role in the mechanisms underlying glucose metabolism disorders in patientswith hyperprolactinemia due to prolactinoma. Larger studies are needed to confirm this potential association.
MATERIAL AND METHODS: The study included 13 patients with prolactinoma without a history of diabetes and in 13 healthy volunteers.All participants underwent a 75-g oral glucose tolerance test (OGTT). Serum glucose, insulin, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were measured at 0, 30, 60, 90, and 120 minutes.
RESULTS: Serum glucose and insulin levels at baseline and during the OGTT were similar in both groups (p > 0.05). GLP-1 levels, including baseline values, area under the curve (AUC), and all time points during OGTT, were also comparable between the groups (p > 0.05).In contrast, baseline GIP (p = 0.024), AUC (p = 0.011), and GIP levels at 30, 90, and 120 minutes were significantly lower in patients withprolactinoma (p = 0.006, p = 0.015, and p = 0.035, respectively).
CONCLUSIONS: These findings suggest that incretins may play a role in the mechanisms underlying glucose metabolism disorders in patientswith hyperprolactinemia due to prolactinoma. Larger studies are needed to confirm this potential association.